



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
3 / SEP 07 2001
H CENTER 1600/2900

Atty. Docket No: 023032/0108

In re patent application of

ROBERTS, Joseph *et al.*

Group Art Unit: 1648

Serial NO:: 09/842,628

Examiner:

Filed: April 27, 2001

For: GENETICALLY ENGINEERED GLUTAMINASE AND ITS USE IN
ANTIVIRAL AND ANTICANCER THERAPY

**AMENDMENT IN RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES UNDER 37 C.F.R. §§ 1.821-1.825**

Assistant Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

Sir:

In response to the Notice to Comply With Requirements for Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed June 5, 2001, please amend the application as follows:

IN THE SPECIFICATION:

Please substitute the current paragraph bridging pages 7 and 8 with the following paragraph:

Figure 1 shows the nucleotide and deduced amino acid sequence of the *Pseudomonas 7A* glutaminase gene. The top strand of the coding DNA sequence (SEQ ID NO: 1) is shown from 5' - 3.' The numbers shown indicate nucleotide base pairs. The deduced peptide sequence is shown below the DNA sequence (SEQ ID NO: 2). The engineered N-terminal methionine residue is not shown.